Skip to main content

HCPCS Level II

HCPCS Level II 2019 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2019, grouped by effective date. Each code's own page carries its full record.

270
Added
65
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2019 (199)

  • A4563 — Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each
  • A5514 — For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each
  • A6460 — Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing
  • A6461 — Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
  • A9513 — Lutetium lu 177, dotatate, therapeutic, 1 millicurie
  • A9589 — Instillation, hexaminolevulinate hydrochloride, 100 mg
  • B4105 — In-line cartridge containing digestive enzyme(s) for enteral feeding, each
  • C1823 — Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads
  • C1890 — No implantable/insertable device used with device-intensive procedures
  • C8937 — Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
  • C9035 — Injection, aripiprazole lauroxil (aristada initio), 1 mg
  • C9036 — Injection, patisiran, 0.1 mg
  • C9037 — Injection, risperidone (perseris), 0.5 mg
  • C9038 — Injection, mogamulizumab-kpkc, 1 mg
  • C9039 — Injection, plazomicin, 5 mg
  • C9407 — Iodine i-131 iobenguane, diagnostic, 1 millicurie
  • C9408 — Iodine i-131 iobenguane, therapeutic, 1 millicurie
  • C9751 — Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)
  • C9752 — Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum
  • C9753 — Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)
  • C9754 — Creation of arteriovenous fistula, percutaneous; direct, any site, including all imaging and radiologic supervision and interpretation, when performed and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization, when performed)
  • C9755 — Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed
  • E0447 — Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)
  • E0467 — Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions
  • G0068 — Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, inotropic, or other intravenous infusion drug or biological (excluding chemotherapy or other highly complex drug or biological) for each infusion drug administration calendar day in the individual's home, each 15 minutes
  • G0069 — Professional services for the administration of subcutaneous immunotherapy or other subcutaneous infusion drug or biological for each infusion drug administration calendar day in the individual's home, each 15 minutes
  • G0070 — Professional services for the administration of intravenous chemotherapy or other intravenous highly complex drug or biological infusion for each infusion drug administration calendar day in the individual's home, each 15 minutes
  • G0071 — Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only
  • G0076 — Brief (20 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0077 — Limited (30 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0078 — Moderate (45 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0079 — Comprehensive (60 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0080 — Extensive (75 minutes) care management home visit for a new patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0081 — Brief (20 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0082 — Limited (30 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0083 — Moderate (45 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0084 — Comprehensive (60 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0085 — Extensive (75 minutes) care management home visit for an existing patient. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0086 — Limited (30 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G0087 — Comprehensive (60 minutes) care management home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility)
  • G2001 — Brief (20 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2002 — Limited (30 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2003 — Moderate (45 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2004 — Comprehensive (60 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2005 — Extensive (75 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2006 — Brief (20 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2007 — Limited (30 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2008 — Moderate (45 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2009 — Comprehensive (60 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2010 — Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment
  • G2011 — Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes
  • G2012 — Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion
  • G2013 — Extensive (75 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2014 — Limited (30 minutes) care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)
  • G2015 — Comprehensive (60 mins) home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility.)
  • J0185 — Injection, aprepitant, 1 mg
  • J0517 — Injection, benralizumab, 1 mg
  • J0567 — Injection, cerliponase alfa, 1 mg
  • J0584 — Injection, burosumab-twza 1 mg
  • J0599 — Injection, c-1 esterase inhibitor (human), (haegarda), 10 units
  • J0841 — Injection, crotalidae immune f(ab')2 (equine), 120 mg
  • J1095 — Injection, dexamethasone 9 percent, intraocular, 1 microgram
  • J1301 — Injection, edaravone, 1 mg
  • J1454 — Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
  • J1628 — Injection, guselkumab, 1 mg
  • J1746 — Injection, ibalizumab-uiyk, 10 mg
  • J2062 — Loxapine for inhalation, 1 mg
  • J2186 — Injection, meropenem and vaborbactam, 10mg/10mg (20mg)
  • J2787 — Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml
  • J2797 — Injection, rolapitant, 0.5 mg
  • J3245 — Injection, tildrakizumab, 1 mg
  • J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
  • J3316 — Injection, triptorelin, extended-release, 3.75 mg
  • J3397 — Injection, vestronidase alfa-vjbk, 1 mg
  • J3398 — Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
  • J3591 — Unclassified drug or biological used for esrd on dialysis
  • J7170 — Injection, emicizumab-kxwh, 0.5 mg
  • J7177 — Injection, human fibrinogen concentrate (fibryga), 1 mg
  • J7203 — Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu
  • J7318 — Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg
  • J7329 — Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg
  • J9044 — Injection, bortezomib, not otherwise specified, 0.1 mg
  • J9057 — Injection, copanlisib, 1 mg
  • J9153 — Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
  • J9173 — Injection, durvalumab, 10 mg
  • J9229 — Injection, inotuzumab ozogamicin, 0.1 mg
  • J9311 — Injection, rituximab 10 mg and hyaluronidase
  • J9312 — Injection, rituximab, 10 mg
  • L8608 — Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system
  • L8698 — Miscellaneous component, supply or accessory for use with total artificial heart system
  • L8701 — Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated
  • L8702 — Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated
  • M1000 — Pain screened as moderate to severe
  • M1001 — Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician
  • M1002 — Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given
  • M1003 — Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
  • M1004 — Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
  • M1005 — Tb screening not performed or results not interpreted, reason not given
  • M1006 — Disease activity not assessed, reason not given
  • M1007 — >=50% of total number of a patient's outpatient ra encounters assessed
  • M1008 — <50% of total number of a patient's outpatient ra encounters assessed
  • M1009 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1010 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1011 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1012 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1013 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1014 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1015 — Discharge/discontinuation of the episode of care documented in the medical record
  • M1016 — Female patients unable to bear children
  • M1017 — Patient admitted to palliative care services
  • M1018 — Patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients
  • M1019 — Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5
  • M1020 — Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq-9 or phq-9m score was not assessed or is greater than or equal to 5
  • M1021 — Patient had only urgent care visits during the performance period
  • M1022 — Patients who were in hospice at any time during the performance period
  • M1023 — Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five
  • M1024 — Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five. either phq-9 or phq-9m score was not assessed or is greater than or equal to five
  • M1025 — Patients who were in hospice at any time during the performance period
  • M1026 — Patients who were in hospice at any time during the performance period
  • M1027 — Imaging of the head (ct or mri) was obtained
  • M1028 — Documentation of patients with primary headache diagnosis and imaging other than ct or mri obtained
  • M1029 — Imaging of the head (ct or mri) was not obtained, reason not given
  • M1030 — Patients with clinical indications for imaging of the head
  • M1031 — Patients with no clinical indications for imaging of the head
  • M1032 — Adults currently taking pharmacotherapy for oud
  • M1033 — Pharmacotherapy for oud initiated after june 30th of performance period
  • M1034 — Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
  • M1035 — Adults who are deliberately phased out of medication assisted treatment (mat) prior to 180 days of continuous treatment
  • M1036 — Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
  • M1037 — Patients with a diagnosis of lumbar spine region cancer at the time of the procedure
  • M1038 — Patients with a diagnosis of lumbar spine region fracture at the time of the procedure
  • M1039 — Patients with a diagnosis of lumbar spine region infection at the time of the procedure
  • M1040 — Patients with a diagnosis of lumbar idiopathic or congenital scoliosis
  • M1041 — Patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
  • M1042 — Functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively
  • M1043 — Functional status was not measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively
  • M1044 — Functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively
  • M1045 — Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was greater than or equal to 37 or knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was greater than or equal to 71
  • M1046 — Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was less than 37 or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was less than 71 postoperatively
  • M1047 — Functional status was measured by the oxford knee score (oks) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively
  • M1048 — Functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively
  • M1049 — Functional status was not measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively
  • M1050 — Functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively
  • M1051 — Patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
  • M1052 — Leg pain was not measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively
  • M1053 — Leg pain was measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively
  • M1054 — Patient had only urgent care visits during the performance period
  • M1055 — Aspirin or another antiplatelet therapy used
  • M1056 — Prescribed anticoagulant medication during the performance period, history of gi bleeding, history of intracranial bleeding, bleeding disorder and specific provider documented reasons: allergy to aspirin or anti-platelets, use of non-steroidal anti-inflammatory agents, drug-drug interaction, uncontrolled hypertension > 180/110 mmhg or gastroesophageal reflux disease
  • M1057 — Aspirin or another antiplatelet therapy not used, reason not given
  • M1058 — Patient was a permanent nursing home resident at any time during the performance period
  • M1059 — Patient was in hospice or receiving palliative care at any time during the performance period
  • M1060 — Patient died prior to the end of the performance period
  • M1061 — Patient pregnancy
  • M1062 — Patient immunocompromised
  • M1063 — Patients receiving high doses of immunosuppressive therapy
  • M1064 — Shingrix vaccine documented as administered or previously received
  • M1065 — Shingrix vaccine was not administered for reasons documented by clinician (e.g. patient administered vaccine other than shingrix, patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons)
  • M1066 — Shingrix vaccine not documented as administered, reason not given
  • M1067 — Hospice services for patient provided any time during the measurement period
  • M1068 — Adults who are not ambulatory
  • M1069 — Patient screened for future fall risk
  • M1070 — Patient not screened for future fall risk, reason not given
  • M1071 — Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminotomy
  • Q2042 — Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
  • Q4183 — Surgigraft, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4184 — Cellesta or cellesta duo, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4185 — Cellesta flowable amnion (25 mg per cc); per 0.5 cc
  • Q4186 — Epifix, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4187 — Epicord, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4188 — Amnioarmor, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4189 — Artacent ac, 1 mg
  • Q4190 — Artacent ac, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4191 — Restorigin, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4192 — Restorigin, 1 cc
  • Q4193 — Coll-e-derm, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4194 — Novachor, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4195 — Puraply, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4196 — Puraply am, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4197 — Puraply xt, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4198 — Genesis amniotic membrane, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4200 — Skin te, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4201 — Matrion, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4202 — Keroxx (2.5g/cc), 1cc
  • Q4203 — Derma-gide, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4204 — Xwrap, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
  • Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
  • Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
  • T4545 — Incontinence product, disposable, penile wrap, each
  • V5171 — Hearing aid, contralateral routing device, monaural, in the ear (ite)
  • V5172 — Hearing aid, contralateral routing device, monaural, in the canal (itc)
  • V5181 — Hearing aid, contralateral routing device, monaural, behind the ear (bte)
  • V5211 — Hearing aid, contralateral routing system, binaural, ite/ite
  • V5212 — Hearing aid, contralateral routing system, binaural, ite/itc
  • V5213 — Hearing aid, contralateral routing system, binaural, ite/bte
  • V5214 — Hearing aid, contralateral routing system, binaural, itc/itc
  • V5215 — Hearing aid, contralateral routing system, binaural, itc/bte
  • V5221 — Hearing aid, contralateral routing system, binaural, bte/bte

Deleted effective January 1, 2019 (45)

  • C8904 — Magnetic resonance imaging without contrast, breast; unilateral
  • C8907 — Magnetic resonance imaging without contrast, breast; bilateral
  • C9014 — Injection, cerliponase alfa, 1 mg
  • C9015 — Injection, c-1 esterase inhibitor (human), haegarda, 10 units
  • C9016 — Injection, triptorelin extended release, 3.75 mg
  • C9024 — Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
  • C9028 — Injection, inotuzumab ozogamicin, 0.1 mg
  • C9029 — Injection, guselkumab, 1 mg
  • C9030 — Injection, copanlisib, 1 mg
  • C9031 — Lutetium lu 177, dotatate, therapeutic, 1 mci
  • C9032 — Injection, voretigene neparvovec-rzyl, 1 billion vector genome
  • C9033 — Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
  • C9034 — Injection, dexamethasone 9%, intraocular, 1 mcg
  • C9275 — Injection, hexaminolevulinate hydrochloride, 100 mg, per study dose
  • C9463 — Injection, aprepitant, 1 mg
  • C9464 — Injection, rolapitant, 0.5 mg
  • C9465 — Hyaluronan or derivative, durolane, for intra-articular injection, per dose
  • C9466 — Injection, benralizumab, 1 mg
  • C9467 — Injection, rituximab and hyaluronidase, 10 mg
  • C9468 — Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u.
  • C9492 — Injection, durvalumab, 10 mg
  • C9493 — Injection, edaravone, 1 mg
  • C9497 — Loxapine, inhalation powder, 10 mg
  • C9741 — Right heart catheterization with implantation of wireless pressure sensor in the pulmonary artery, including any type of measurement, angiography, imaging supervision, interpretation, and report
  • C9744 — Ultrasound, abdominal, with contrast
  • C9748 — Transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy
  • C9750 — Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode)
  • G9534 — Advanced brain imaging (cta, ct, mra or mri) was not ordered
  • G9535 — Patients with a normal neurological examination
  • G9536 — Documentation of medical reason(s) for ordering an advanced brain imaging study (i.e., patient has an abnormal neurological examination; patient has the coexistence of seizures, or both; recent onset of severe headache; change in the type of headache; signs of increased intracranial pressure (e.g., papilledema, absent venous pulsations on funduscopic examination, altered mental status, focal neurologic deficits, signs of meningeal irritation); hiv-positive patients with a new type of headache; immunocompromised patient with unexplained headache symptoms; patient on coagulopathy/anti-coagulation or anti-platelet therapy; very young patients with unexplained headache symptoms)
  • G9538 — Advanced brain imaging (cta, ct, mra or mri) was ordered
  • G9686 — Onsite nursing facility conference, that is separate and distinct from an evaluation and management visit, including qualified practitioner and at least one member of the nursing facility interdisciplinary care team
  • J0833 — Injection, cosyntropin, not otherwise specified, 0.25 mg
  • J9310 — Injection, rituximab, 100 mg
  • K0903 — For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each
  • Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
  • Q4131 — Epifix or epicord, per square centimeter
  • Q4172 — Puraply or puraply am, per square centimeter
  • Q9993 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
  • Q9994 — In-line cartridge containing digestive enzyme(s) for enteral feeding, each
  • Q9995 — Injection, emicizumab-kxwh, 0.5 mg
  • V5170 — Hearing aid, cros, in the ear
  • V5180 — Hearing aid, cros, behind the ear
  • V5210 — Hearing aid, bicros, in the ear
  • V5220 — Hearing aid, bicros, behind the ear

Added effective April 1, 2019 (8)

  • C9040 — Injection, fremanezumab-vfrm, 1mg
  • C9041 — Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg
  • C9042 — Injection, bendamustine hcl (belrapzo), 1 mg
  • C9043 — Injection, levoleucovorin, 1 mg
  • C9044 — Injection, cemiplimab-rwlc, 1 mg
  • C9045 — Injection, moxetumomab pasudotox-tdfk, 0.01 mg
  • C9046 — Cocaine hydrochloride nasal solution (goprelto), 1 mg
  • C9141 — Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.

Added effective July 1, 2019 (17)

  • C9047 — Injection, caplacizumab-yhdp, 1 mg
  • C9048 — Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
  • C9049 — Injection, tagraxofusp-erzs, 10 mcg
  • C9050 — Injection, emapalumab-lzsg, 1 mg
  • C9051 — Injection, omadacycline, 1 mg
  • C9052 — Injection, ravulizumab-cwvz, 10 mg
  • C9756 — Intraoperative near-infrared fluorescence lymphatic mapping of lymph node(s) (sentinel or tumor draining) with administration of indocyanine green (icg) (list separately in addition to code for primary procedure)
  • J1444 — Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron
  • J7208 — Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.
  • J7677 — Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
  • J9030 — Bcg live intravesical instillation, 1 mg
  • J9036 — Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
  • J9356 — Injection, trastuzumab, 10 mg and hyaluronidase-oysk
  • Q5112 — Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
  • Q5113 — Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
  • Q5114 — Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
  • Q5115 — Injection, rituximab-abbs, biosimilar, (truxima), 10 mg

Deleted effective July 1, 2019 (4)

  • C9042 — Injection, bendamustine hcl (belrapzo), 1 mg
  • C9141 — Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.
  • C9746 — Transperineal implantation of permanent adjustable balloon continence device, with cystourethroscopy, when performed and/or fluoroscopy, when performed
  • J9031 — Bcg (intravesical) per instillation

Added effective October 1, 2019 (45)

  • J0121 — Injection, omadacycline, 1 mg
  • J0122 — Injection, eravacycline, 1 mg
  • J0222 — Injection, patisiran, 0.1 mg
  • J0291 — Injection, plazomicin, 5 mg
  • J0593 — Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
  • J0642 — Injection, levoleucovorin (khapzory), 0.5 mg
  • J1096 — Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
  • J1097 — Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml
  • J1303 — Injection, ravulizumab-cwvz, 10 mg
  • J1943 — Injection, aripiprazole lauroxil, (aristada initio), 1 mg
  • J1944 — Injection, aripiprazole lauroxil, (aristada), 1 mg
  • J2798 — Injection, risperidone, (perseris), 0.5 mg
  • J3031 — Injection, fremanezumab-vfrm, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
  • J3111 — Injection, romosozumab-aqqg, 1 mg
  • J7314 — Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mg
  • J7331 — Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg
  • J7332 — Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg
  • J7401 — Mometasone furoate sinus implant, 10 micrograms
  • J9118 — Injection, calaspargase pegol-mknl, 10 units
  • J9119 — Injection, cemiplimab-rwlc, 1 mg
  • J9204 — Injection, mogamulizumab-kpkc, 1 mg
  • J9210 — Injection, emapalumab-lzsg, 1 mg
  • J9269 — Injection, tagraxofusp-erzs, 10 micrograms
  • J9313 — Injection, moxetumomab pasudotox-tdfk, 0.01 mg
  • Q4205 — Membrane graft or membrane wrap, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4206 — Fluid flow or fluid gf, 1 cc
  • Q4208 — Novafix, per square cenitmeter (add-on, list separately in addition to primary procedure)
  • Q4209 — Surgraft, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4210 — Axolotl graft or axolotl dualgraft, per square centimeter
  • Q4211 — Amnion bio or axobiomembrane, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4212 — Allogen, per cc
  • Q4213 — Ascent, 0.5 mg
  • Q4214 — Cellesta cord, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4215 — Axolotl ambient or axolotl cryo, 0.1 mg
  • Q4216 — Artacent cord, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4217 — Woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4218 — Surgicord, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4219 — Surgigraft-dual, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4220 — Bellacell hd or surederm, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4221 — Amniowrap2, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4222 — Progenamatrix, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4226 — Myown skin, includes harvesting and preparation procedures, per square centimeter
  • Q5116 — Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
  • Q5117 — Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
  • Q5118 — Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

Deleted effective October 1, 2019 (16)

  • C9035 — Injection, aripiprazole lauroxil (aristada initio), 1 mg
  • C9036 — Injection, patisiran, 0.1 mg
  • C9037 — Injection, risperidone (perseris), 0.5 mg
  • C9038 — Injection, mogamulizumab-kpkc, 1 mg
  • C9039 — Injection, plazomicin, 5 mg
  • C9040 — Injection, fremanezumab-vfrm, 1mg
  • C9044 — Injection, cemiplimab-rwlc, 1 mg
  • C9045 — Injection, moxetumomab pasudotox-tdfk, 0.01 mg
  • C9048 — Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
  • C9049 — Injection, tagraxofusp-erzs, 10 mcg
  • C9050 — Injection, emapalumab-lzsg, 1 mg
  • C9051 — Injection, omadacycline, 1 mg
  • C9052 — Injection, ravulizumab-cwvz, 10 mg
  • C9447 — Injection, phenylephrine and ketorolac, 4 ml vial
  • J1942 — Injection, aripiprazole lauroxil, 1 mg
  • S1090 — Mometasone furoate sinus implant, 370 micrograms

Added effective November 15, 2019 (1)

  • C9058 — Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2019
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger